key: cord-0907116-80m78jh2
authors: Srivastava, Sukrit; Verma, Sonia; Kamthania, Mohit; Kaur, Rupinder; Badyal, Ruchi Kiran; Saxena, Ajay Kumar; Shin, Ho-Joon; Kolbe, Michael; Pandey, Kailash C
title: Structural basis to design multi-epitope vaccines against Novel Coronavirus 19 (COVID19) infection, the ongoing pandemic emergency: an in silico approach
date: 2020-04-16
journal: bioRxiv
DOI: 10.1101/2020.04.01.019299
sha: 083f1586159a29e5900019f13fbc4e19d82c6ac4
doc_id: 907116
cord_uid: 80m78jh2

The 2019 novel coronavirus (COVID19 / Wuhan coronavirus), officially named as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), is a positive-sense single-stranded RNA coronavirus. SARS-CoV-2 causes the contagious COVID19 disease also known as 2019-nCoV acute respiratory disease and has led to the ongoing 2019–20 pandemic COVID19 outbreak. The effective counter measures against SARS-CoV-2 infection require the design and development of specific and effective vaccine candidate. In the present study, we have screened and shortlisted 38 CTL, 33 HTL and 12 B cell epitopes from the eleven Protein sequences of SARS-CoV-2 by utilizing different in silico tools. The screened epitopes were further validated for their binding with their respective HLA allele binders and TAP (Transporter associated with antigen processing) molecule by molecular docking. The shortlisted screened epitopes were further utilized to design novel two multi-epitope vaccines (MEVs) composed of CTL, HTL and B cell epitopes overlaps with potential to elicit humoral as well as cellular immune response against SARS-CoV-2. To enhance the immune response for our vaccine design, truncated (residues 10-153) Onchocerca volvulus activation-associated secreted protein-1 (Ov-ASP-1) has been utilized as an adjuvant at N terminal of both the MEVs. Further molecular models for both the MEVs were prepared and validated for their stable molecular interactions with Toll-Like Receptor 3 (TLR 3). The codon-optimized cDNA of both the MEVs were further analyzed for their potential of high level of expression in a human cell line. The present study is very significant in terms of molecular designing of prospective CTL and HTL vaccine against SARS-CoV-2 infection with the potential to elicit cellular as well as humoral immune response. (SARS-CoV-2), Coronavirus, Human Transporter associated with antigen processing (TAP), Toll-Like Receptor (TLR), Epitope, Immunoinformatics, Molecular Docking, Molecular dynamics simulation, Multi-epitope Vaccine Graphical abstract The designed CTL (Cytotoxic T lymphocyte) and HTL (Helper T lymphocyte) multi-epitope vaccines (MEV) against COVID19 infection. Both the CTL and HTL MEV models show a very stable and well fit conformational complex formation tendency with the Toll like receptor 3. CTL and HTL MEVs: ribbon; Toll like receptor 3: gray cartoon; Adjuvant [truncated (residues 10-153) Onchocerca volvulus activation-associated secreted protein-1]: orange ribbon regions; Epitopes: cyan ribbons regions; 6xHis Tag: magenta ribbon regions.

The novel coronavirus (COVID19), officially named as Severe Acute Respiratory NetMHCIIpan) and generate "Percentile rank" and a "total score" respectively. 273

The screening is based on the total amount of cleavage sites in the Immunogenicity of all the screened CTL epitopes was also obtained by 282 using "MHC I Immunogenicity" tool of IEDB 283 (http://tools.iedb.org/immunogenicity/) with all the parameters set to default 284 analyzing 1st, 2nd, and C-terminus amino acids of the given screened epitope 285 of IEDB (http://tools.iedb.org/population/) was used to elucidate the world human 303 population coverage by the shortlisted 38 CTL and 33 HTL epitopes derived from 304 nine SARS-CoV-2 proteins (Bui et al., 2006) . T cells recognize the complex 305 between a specific major MHC molecule and a particular pathogen-derived 306 epitope. The given epitope will elicit a response only in an individual that express 307 an MHC molecule, which is capable of binding that particular epitope. This 308 denominated MHC restriction of T cell responses and the MHC polymorphism 309 provides the basis for population coverage study. The MHC types are expressed 310 14 at dramatically different frequencies in different ethnicities. Hence a vaccine with 311 larger population coverage could be of greater importance (Sturniolo et al., 312 1999) . Clinical administration of multiple-epitopes involving both the CTL and the 313 HTL epitopes are predicted here to have a greater probability of larger human 314 population coverage worldwide. 315

Sequence-based B Cell epitope prediction. Protein sequence-based method 318 "Bepipred Linear Epitope Prediction" was utilized to screen linear B cell epitopes 319 from eleven different SARS-CoV-2 proteins. The tool "B Cell Epitope Prediction 320

Tools" of IEDB server (http://tools.iedb.org/bcell/) was utilized. In this screening, 321 the parameters such as hydrophilicity, flexibility, accessibility, turns, exposed 322 surface, polarity and the antigenic propensity of the polypeptides is correlated 323 with its location in the protein. This allows the search for continuous epitopes 324 prediction from protein sequence. The prediction is base on the propensity scales 325 for each of the 20 amino acids. For a window size n, the i -(n-1)/2 neighboring 326 residues on each side of residue i are used to compute the score for the residue 327 i. The method "Bepipred Linear Epitope Prediction" utilized here is based on the 328 propensity scale method as well as the physiochemical properties of the given 329 antigenic sequence to screen potential epitopes (Larsen et al., 2006) . 330 331

Epitope conservation analysis. The shortlisted CTL, HTL and B cell epitopes 333 screened from eleven SARS-CoV-2 proteins were analyzed for the conservancy 334 of their amino acid sequence by "Epitope Conservancy Analysis" tool 335 of templet proteins is based on TM-score of the structural alignment between the 508 query structure model and known structures. The RMSD is the RMSD between 509 templet residues and query residues that are structurally aligned by TM-align. 510

The refinement of both the generated MEV models was performed by 511

(https://zhanglab.ccmb.med.umich.edu/ModRefiner/) and 512

GalaxyRefine tool (http://galaxy.seoklab.org/cgi-bin/submit.cgi?type=REFINE) 513 The GalaxyRefine tool refines the query tertiary structure by repeated 519 structure perturbation as well as by utilizing the subsequent structural relaxation 520 by the molecular dynamics simulation. The tool GalaxyRefine generates reliable 521 core structures from multiple templates and then re-builds unreliable loops or 522 termini by using an optimization-based refinement method (Ko et 

The molecular docking study of chosen CTL and HTL epitopes with their 787 respective HLA class I and II allele binders was performed by PatchDock tool. 788

The study revealed a significant molecular interaction between all the chosen 789 epitopes and their HLA allele binders showing multiple hydrogen bond formations 790 (Fig.3) . Furthermore, the B-factor analysis of all the epitope-HLA allele 791 complexes has also shown the epitope ligand to have stable (blue) binding The molecular docking interaction analysis of the chosen CTL epitopes with the 894 TAP transporter cavity has shown a significantly strong molecular interaction with 895 several hydrogen bonds formation at different sites of the TAP transporter cavity. 896

Two sites of interaction were of particular interest, one closer to the cytoplasmic 897 end and another closer to the ER lumen (Fig.5) . This study confirms the 898 feasibility of transportation of chosen CTL epitopes from the cytoplasm to the ER 899 lumen which is an essential event for the representation of epitope by the HLA 900 allele molecules on the surface of antigen-presenting cells. (Table 5) . The epitopes are shown in cyan. The adjuvant (Ov-ASP-1) is shown in orange. 992

The linkers are shown in gray and 6xHis tag is shown in magenta. Both the 993 cartoon and surface presentation of both the MEVs are shown. 994

The ABCs of immunology: structure and function 1279 of TAP, the transporter associated with antigen processing

Assembly and export of MHC 1282 class I peptide ligands

The SWISS-MODEL 1284 Workspace: A web-based environment for protein structure homology 1285 modelling

The molecular structure of the Toll-like receptor 3 ligand-1288 binding domain

QMEAN: A comprehensive 1291 scoring function for model quality assessment

1294 Predicting population coverage of T-cell epitope-based diagnostics and 1295 vaccines

Development of an epitope 1297 conservancy analysis tool to facilitate the design of epitope-based 1298 diagnostics and vaccines

Properties of MHC class I presented peptides 1301 that enhance immunogenicity

The FF14SB force field

Fusion protein linkers: property, 1306 design and functionality

Innate immunity: structure 1309 and function of TLRs. Medecine sciences: M/S

Designing of interferon-gamma inducing 1311 MHC class-II binders

Improving the Physical Realism and Structural 1313 Accuracy of Protein Models by a Two-step Atomic-level Energy 1314 Minimization

Efficient Unbound Docking of Rigid 1316

Proceedings of the 2'nd Workshop on 1317 Algorithms in Bioinformatics(WABI)

Preferential expression and function of Toll-like receptor 3 in human 1321 astrocytes

Protein identification and analysis tools on the 1324 ExPASy server

A Sequence Homology and Bioinformatic Approach Can Predict 1327 Candidate Targets for Immune Responses to SARS-CoV-2. Cell Host & 1328 Microbe

A truncated fragment of Ov-ASP-1 consisting 1331 of the core pathogenesis-related-1 (PR-1) domain maintains adjuvanticity 1332 as the full-length protein

1334 and Open Source Drug Discovery Consortium, 2013. In silico approach for 1335 predicting toxicity of peptides and proteins

Immunoinformatics analysis and in silico 1338 designing of a novel multi-epitope peptide vaccine against Staphylococcus 1339 aureus. Infection

Recombinant Ov-1342 ASP-1, a Th1-biased protein adjuvant derived from the helminth 1343 Onchocerca volvulus, can directly bind and activate antigen-presenting 1344 cells

NetMHCpan, a method for MHC class I binding 1347 prediction beyond humans

A flexible peptide linker 1349 enhances the immunoreactivity of two copies HBsAg preS1 (21-47) fusion 1350 protein

VaxiJen: a server for prediction of 1352 protective antigens, tumour antigens and subunit vaccines

GalaxyWEB server for protein structure 1355 prediction and refinement

New ways to boost molecular dynamics 1358 simulations

Reliable B cell 1360 epitope predictions: impacts of method development and improved 1361 benchmarking

Improved method for predicting linear B-1363 cell epitopes

1365 rOv-ASP-1, a recombinant secreted protein of the helminth Onchocerca 1366 volvulus, is a potent adjuvant for inducing antibodies to ovalbumin, HIV-1 1367 polypeptide and SARS-CoV peptide antigens

ff14SB: improving the accuracy of protein side chain 1371 and backbone parameters from ff99SB

Synonymous codon usage pattern in 1374 glycoprotein gene of rabies virus

VaccineDA: Prediction, design and genome-wide screening of 1377 oligodeoxynucleotide-based vaccine adjuvants. Scientific reports, 5, 1378 p.12478. 1379 NCBI protein sequence database: SARS-CoV-2 (Severe acute respiratory 1380 syndrome coronavirus 2) Sequences

Prediction of MHC class II 1383 binding affinity using SMM-align, a novel stabilization matrix alignment 1384 method

Structure of the Transporter 1386 associated with antigen processing trapped by herpes simplex virus. eLife

Identifying 1389 MHC class I epitopes by predicting the TAP transport efficiency of epitope 1390 precursors

UCSF Chimera-a visualization 1393 system for exploratory research and analysis

ElliPro: a new structure-based tool for the prediction of antibody epitopes

PyMOL: The PyMOL Molecular Graphics System, Version 2.0 Schrödinger

Stereochemical criteria for 1400 polypeptide and protein chain conformations: II. Allowed conformations for 1401 a pair of peptide units

I-TASSER: a unified platform for 1403 automated protein structure and function prediction

Structure validation 1407 by Calpha geometry: phi,psi and Cbeta deviation

AlgPred: prediction of allergenic proteins and mapping 1410 of IgE epitopes

PatchDock and 1412 SymmDock: servers for rigid and symmetric docking

Improved PEP-1415 FOLD approach for peptide and miniprotein structure prediction

Prediction of protein 1418 structure and interaction by GALAXY protein modeling programs

Quantitative peptide binding motifs for 19 human and mouse 1422 MHC class I molecules derived using positional scanning combinatorial 1423 peptide libraries

Fast, scalable generation of high-quality protein multiple 1427 sequence alignments using Clustal Omega. Molecular systems biology

Design of 1431 novel multi-epitope vaccines against severe acute respiratory syndrome 1432 validated through multistage molecular interaction and dynamics

Structural basis of development of multi-epitope vaccine against middle 1436 east respiratory syndrome using in silico approach. Infection and drug 1437 resistance

Generation of tissue-specific and promiscuous HLA ligand 1441 databases using DNA microarrays and virtual HLA class II matrices

Modeling the MHC class 1445 I pathway by combining predictions of proteasomal cleavage, TAP 1446 transport and MHC class I binding

Toll-like receptor 3 signaling via TRIF 1449 contributes to a protective innate immune response to severe acute 1450 respiratory syndrome coronavirus infection

Efficient particle-mesh 1452 Ewald based approach to fixed and induced dipolar interactions. The

Peptide binding predictions for HLA DR, DP and DQ molecules

Predicting protein contact map using evolutionary and 1460 physical constraints by integer programming

Coronavirus disease 2019

Computational identification of rare codons of Escherichia 1468 coli based on codon pairs preference

Overlapping residue analysis. Amino acid sequence overlap analysis amongst 725 the shortlisted CTL, HTL and B cell epitopes from eleven SARS-CoV-2 proteins 726 was performed by the Multiple Sequence Alignment (MSA) analysis tool Clustal 727Omega. The analysis has shown that several epitopes of CTL, HTL and B cell 728 were having amino acid sequences overlap. The CTL, HTL and B cell epitopes 729 having two or more than two amino acid residues overlap are shown in Fig.2 . Tertiary structure modeling and refinement of MEVs. 3D homology models were 1029 generated for both the CTL and HTL MEVs by utilizing the I-TASSER modeling 1030 tool (Fig.7) . The models were generated for CTL Multi-epitope vaccine (PDB hit 1031 5n8pA, Norm. Z-score of 1.49, Cov of 0.92, TM-score of 0.916 and RMSD of 1032 1.04 Å) and HTL Multi-epitope vaccine (PDB hit 5n8pA, Norm. Z-score of 1.52, 1033Cov of 0.97, TM-score of 0.916 and RMSD of 1.04 Å). 1034Both the generated CTL and HTL 3D models were further refined by 1035ModRefiner to fix any gaps and then followed by GalaxyRefine refinement. The 1036 refinement by ModRefiner showed the TM-score of 0.9189 and 0.9498 for the 1037 CTL and HTL models respectively, hence being close to 1, the initial and the 1038 refined models were structurally similar. After refinement, the RMSD for CTL and 1039HTL models with respect to the initial model was 3.367Å and 2.318Å 1040 48 respectively. Further, both the CTL and HTL MEVs models were refined by 1041 were analyzed by the RAMPAGE analysis tool after refinement. The refined CTL 1053 MEV model was found to have 85.8% residues in favored region, 11.3% residues 1054 in allowed region, and only 3.0% residues in the outlier region; while the refined 1055 HTL MEV model was found to have 88.9% of residues in favored region, 8.9% 1056 residues in allowed region, and only 2.2% residues in the outlier region ( have shown all the selected epitopes to be non-toxic (Non-Toxin) as well as they 1253show significant conservancy with high immunogenicity. 1254 1255Supplementary table S10. Shortlisted high scoring HTL epitopes (MHC-II 1256Binding Predictions). Selected high "Percentile rank" HTL epitopes with their 1257 respective HLA class II alleles binders predicted by the "MHC-II Binding 1258Predictions" tool of IEDB are listed. In-silico analysis has shown all the selected 1259 epitopes to be non-toxic (Non-Toxin) as well as they show significant 1260conservancy.

Supplementary table S11. Shortlisted B Cell epitopes (BepiPred Linear B 1263Cell Prediction). B cell linear epitopes with length of 4 to 20 amino acids, 1264 predicted by the "BepiPred Linear B Cell Prediction" IEDB tool, from eleven 1265 SARS-CoV-2 proteins, are listed here. In-silico analysis has shown all the 1266 selected epitopes to be non-toxic (Non-Toxin) as well as they show significant 1267 amino acid sequence conservancy.